Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alnylam Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network

77 comunicati stampa

Guarda tutti i comunicati
02/09/2026
Eventi
Web e Social Network
Biotecnologia
Sanità
Salute
Farmaceutica
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/08/2026
Eventi
Industria
Cardiologia
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Igiene alimentare
Medicina - Varie
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
24/08/2026
Eventi
Analisi di mercato
Salute
Medicina - Varie
Scienza
Farmaceutica
Cardiologia
Biotecnologia
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/07/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Biotecnologia
Scienza
Farmaceutica
Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
16/07/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
15/07/2026
Eventi
Industria
Psichiatria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
12/06/2026
Web e Social Network
Eventi
Biotecnologia
Salute
Scienza
Farmaceutica
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
19/05/2026
Information Technology
Associazioni/Professionisti
Scienza
Tecnica
Sanità
Farmaceutica
Ecologia/Salute ambientale
Biotecnologia
Tecnologie Varie
Salute
Industria
Alnylam Issues 2025 Corporate Responsibility Report
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
12/05/2026
Eventi
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/05/2026
Web e Social Network
Eventi
Industria
Salute
Scienza
Farmaceutica
Biotecnologia
Alnylam to Webcast Presentations at Upcoming Investor Conferences
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0